Pulmonary hypertension - chronic thromboembolic pulmonary hypertension

The PBS subsidises riociguat for patients with chronic thromboembolic pulmonary hypertension (CTEPH).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with riociguat under the National Health Act 1953, section 100 for patients aged 18 years or over with CTEPH.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing riociguat.

Section 100 arrangements

riociguat

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Authority applications

All patients applying for riociguat treatment must be treated in a centre with expertise in the management of CTEPH.

Applying for initial treatment

Apply for initial authority approval to prescribe PBS-subsidised riociguat to treat CTEPH in writing and either:

All written applications must include the completed:

Applying for continuing treatment

Apply for continuing authority approval to prescribe PBS-subsidised riociguat to treat CTEPH in writing and either:

All written applications must include the completed:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 August 2023.
QC 36186